ATE286541T1 - Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem - Google Patents

Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem

Info

Publication number
ATE286541T1
ATE286541T1 AT01938296T AT01938296T ATE286541T1 AT E286541 T1 ATE286541 T1 AT E286541T1 AT 01938296 T AT01938296 T AT 01938296T AT 01938296 T AT01938296 T AT 01938296T AT E286541 T1 ATE286541 T1 AT E286541T1
Authority
AT
Austria
Prior art keywords
diagnostic
prostate cancer
test system
suitable test
kit
Prior art date
Application number
AT01938296T
Other languages
English (en)
Inventor
Olivier Cussenot
Alain Latil
Karine Chantrel-Groussard
Original Assignee
Urogene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene filed Critical Urogene
Application granted granted Critical
Publication of ATE286541T1 publication Critical patent/ATE286541T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT01938296T 2000-06-27 2001-05-22 Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem ATE286541T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0008266A FR2810677B1 (fr) 2000-06-27 2000-06-27 Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre
PCT/FR2001/001566 WO2002000929A1 (fr) 2000-06-27 2001-05-22 Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre

Publications (1)

Publication Number Publication Date
ATE286541T1 true ATE286541T1 (de) 2005-01-15

Family

ID=8851762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938296T ATE286541T1 (de) 2000-06-27 2001-05-22 Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem

Country Status (6)

Country Link
EP (1) EP1294941B1 (de)
AT (1) ATE286541T1 (de)
AU (1) AU2001263992A1 (de)
DE (1) DE60108245D1 (de)
FR (1) FR2810677B1 (de)
WO (1) WO2002000929A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076080B2 (en) 2002-05-21 2011-12-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
FR2849382A1 (fr) * 2002-12-26 2004-07-02 Urogene Utilisation du gene htr2b pour le traitement du cancer de la prostate
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
US8273539B2 (en) 2006-09-25 2012-09-25 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
FR2981662A1 (fr) * 2011-10-20 2013-04-26 Assist Publ Hopitaux De Paris Methode de quantification de marqueurs renaux par dosage urinaire.
EP2791359B1 (de) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Krebsdiagnostik mit nichtcodierenden transkripten
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
EP3504348B1 (de) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Verwendung von genomischen signaturen zur vorhersage des ansprechens von patienten mit prostatakrebs auf postoperative strahlentherapie
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
CN113025721A (zh) * 2021-04-28 2021-06-25 苏州宏元生物科技有限公司 一种前列腺癌诊断和预后评估试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006750A1 (en) * 1993-09-03 1995-03-09 Cellpro, Incorporated Methods for quantifying the number of cells containing a selected nucleic acid sequence in a heterogenous population of cells
JP2000500329A (ja) * 1995-10-23 2000-01-18 インペリアル キャンサー リサーチ テクノロジィ リミテッド 癌罹病性の診断およびその治療
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6140049A (en) * 1996-11-21 2000-10-31 Genset Detection and early diagnosis of prostate cancer
JPH10276780A (ja) * 1997-04-01 1998-10-20 Sumitomo Metal Ind Ltd PSA mRNAの検出方法及び検出キット
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer

Also Published As

Publication number Publication date
FR2810677B1 (fr) 2004-10-01
DE60108245D1 (de) 2005-02-10
EP1294941A1 (de) 2003-03-26
WO2002000929A1 (fr) 2002-01-03
FR2810677A1 (fr) 2001-12-28
AU2001263992A1 (en) 2002-01-08
EP1294941B1 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60108245D1 (de) Diagnostisches in vitro-verfahren für prostatakrebs sowie hierfür geeignetes testsystem
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
IL149171A0 (en) Elisa for vegf
CA2425761A1 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
Breul et al. Prostate-specific antigen in urine
BR0010068A (pt) Sistema de identificação do marcador fenotìpico e biológico
WO2004031414A3 (en) Method for diagnosing prostate cancer
EP1362124A4 (de) Verfahren und sonden für den nachweis von krebs
WO2003069307A3 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
ATE341349T1 (de) Sonde für die mikrodialyse
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
EP1107006A4 (de) Verfahren zur diagnose von knochenmetastasen und malignen tumoren
FR2810114B1 (fr) Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
NO942653L (no) Fremgangsmåte for å anslå det biologiske potensialet til en valgt carsinoma hos en pasient
Cohen et al. The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need
ATE409002T1 (de) Gerät für prostatekrebsdiagnose
WO2002072752A3 (en) Forms of prostate specific antigens and methods for their detection
Joniau et al. 259 The effect of chemoprevention on PSA and clinical management in patients with high grade prostatic intraepithelial neoplasia
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
EP1724579A3 (de) Verfahren zur Diagnose von Prostatakrebs und zur Analyse von Prostatatumoren
Mladenov et al. The diagnosis, biopsy and treatment follow-up by ultrasound in patients with prostatic carcinoma
Roscigno et al. 260 Isolated mono-and pluri-focal high grade prostatic intraepithelial neoplasia (HGPIN) on initial extended prostate needle biopsies: factors predicting cancer detection on extended re-biopsy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties